APA Guidelines Bundle

Treatment of Patients with Schizophrenia

APA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1303678

Contents of this Issue

Navigation

Page 21 of 29

22 Treatment Long-acting injectable antipsychotic medications: dosing* (cont'd) Olanzapine Zyprexa Relprevv 10 mg/day orally, 210 mg every 2 weeks for four doses, or 405 mg every 4 weeks 15 mg/day orally, 300 mg every 2 weeks for four doses 20 mg/day orally, 300 mg every 2 weeks Determined by oral dose Paliperidone palmitate Invega Sustenna 3 mg oral paliperidone, give 39–78 mg IM 6 mg oral, give 117 mg IM 9 mg oral, give 156 mg IM 12 mg oral, give 234 mg IM 234 mg IM on day 1 and 156 mg IM 1 week later, both administered in the deltoid muscle Paliperidone palmitate Invega Trinza Conversion from monthly Invega Sustenna to every 3-month injections of Invega Trinza: 78 mg, give 273 mg 117 mg, give 410 mg 156 mg, give 546 mg 234 mg, give 819 mg Dependent on last dose of monthly paliperidone Risperidone Risperdal Consta Oral risperidone to Risperidone Consta IM: ≤3 mg/day, give 25 mg/2 weeks >3 to ≤5 mg/day, give 37.5 mg/2 weeks >5 mg/day, give 50 mg/2 weeks 25 every 2 weeks Risperidone Perseris Oral risperidone to subcutaneous risperidone extended release: 3 mg/day, give 90 mg/monthly 4 mg/day, give 120 mg/monthly Determined by oral dose * This table includes information compiled from multiple sources. Detailed information on such issues as dose regimen, dose adjustments, medication administration procedures, handling precautions, and storage can be found in product labeling. It is recommended that readers consult product labeling information for authoritative information on these medications.

Articles in this issue

Archives of this issue

view archives of APA Guidelines Bundle - Treatment of Patients with Schizophrenia